Welcome to LookChem.com Sign In|Join Free

CAS

  • or

174222-78-7

(R)-2-(dimethylamino)-3-phenylpropanoic acid, commonly known as Naproxen, is an organic carboxylic acid with the molecular formula C11H15NO2. It is widely recognized as a nonsteroidal anti-inflammatory drug (NSAID) that operates by inhibiting the production of prostaglandins, which are responsible for inflammation, pain, and fever in the body.

174222-78-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 174222-78-7 Structure

  • Basic information

    1. Product Name: (R)-2-(dimethylamino)-3-phenylpropanoic acid
    2. Synonyms: (R)-2-(dimethylamino)-3-phenylpropanoic acid
    3. CAS NO:174222-78-7
    4. Molecular Formula:
    5. Molecular Weight: 193.246
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 174222-78-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: (R)-2-(dimethylamino)-3-phenylpropanoic acid(CAS DataBase Reference)
    10. NIST Chemistry Reference: (R)-2-(dimethylamino)-3-phenylpropanoic acid(174222-78-7)
    11. EPA Substance Registry System: (R)-2-(dimethylamino)-3-phenylpropanoic acid(174222-78-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 174222-78-7(Hazardous Substances Data)

174222-78-7 Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-(dimethylamino)-3-phenylpropanoic acid is used as an anti-inflammatory agent for its ability to alleviate mild to moderate pain, inflammation, and stiffness associated with various conditions such as arthritis, menstrual cramps, and other inflammatory disorders. Its effectiveness in reducing discomfort and pain makes it a popular choice among healthcare professionals and patients.
Additionally, (R)-2-(dimethylamino)-3-phenylpropanoic acid is used as an analgesic for its pain-relieving properties and as an antipyretic to help reduce fever. However, it is important to note that the use of (R)-2-(dimethylamino)-3-phenylpropanoic acid may come with side effects like stomach upset, nausea, and dizziness, and should be taken under the guidance of a healthcare professional to ensure safe and effective treatment.

Check Digit Verification of cas no

The CAS Registry Mumber 174222-78-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,2,2 and 2 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 174222-78:
(8*1)+(7*7)+(6*4)+(5*2)+(4*2)+(3*2)+(2*7)+(1*8)=127
127 % 10 = 7
So 174222-78-7 is a valid CAS Registry Number.

174222-78-7Downstream Products

174222-78-7Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

-

Paragraph 0334; 0469-0470, (2017/07/05)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 86, (2012/02/15)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 237, (2012/04/10)

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 175, (2011/06/16)

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 88, (2011/06/16)

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 83, (2011/07/07)

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 145, (2010/11/04)

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 134, (2010/12/26)

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 92, (2010/12/26)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

-

Page/Page column 51, (2010/10/19)

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 174222-78-7